Opinion
Video
Next Steps: Post-Frontline Therapies and Resistance in ALK+ NSCLC
Panelists discuss how alectinib use in the adjuvant setting might shift sequencing strategies in metastatic ALK+ non–small cell lung cancer (NSCLC) and how resistance mutations influence post-frontline therapy selection.
Sequencing Strategies and Resistance Management
Key Themes:
- Impact of adjuvant alectinib use (ALINA) on sequencing strategies
- Selection of post-frontline therapies after ALK inhibitor progression
- Role of resistance mutations in therapy selection
- Emerging data on NVL-655 (from ESMO 2024)
Notable Insights:
- Dr Dietrich explored how adjuvant ALK inhibitor exposure might influence frontline metastatic therapy selection
Dr Lovly discussed strategies for selecting therapies after progression, including considerations of resistance mutations and data on NVL-655
Related Content
